TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™! We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, *"TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines"* will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.
We are delighted to announce our sponsorship
We are delighted that we can make a small contribution to the important work of Dr. Scott Tighe, Technical Director at the Advanced Genomics Lab at the University of Vermont, NASA-ISS uTitan Payload developer and Group leader Extreme Microbiome Project. In December 2023, two of RNAssist’s molecular stabilisation reagents will be taken to the International Space Station (ISS) on SpaceX Dragon SpX-29 where they will be tested on microbial samples as part of a larger study in collaboration with NASA.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com